Prima BioMed Limited (ASX:PRR; NASDAQ:PBMD) says it has joined forces with a Japanese spin-off from NEC Corp called CYTLIMIC.
Under the terms of the deal Prima will provide its lead product, an immune control mechanism called IMP321 to CYTLIMIC who will fund a new pre-clinical and development study for the drug.
It is hoped the collaboration will produce a peptide vaccine for cancer immunotherapy.
Prima Biomed made a net loss of $62 million to the end of June 2016.
